Picture of Antidepressants Too Rosy?
Review Shows "Selective" Reporting of Studies Inflates Effectiveness of Antidepressants
WebMD News Archive
Jan. 16, 2008 -- Commonly prescribed antidepressants may not work as
well as published studies suggest, according to new research.
"Selective" reporting of study results inflates the effectiveness of
antidepressants, researchers found.
"I don't want people to think these drugs are not effective, that's
not the take-away," Erick Turner, MD, the study's lead author, tells WebMD.
"The drugs are still effective, but less so than what would be apparent
from the medical literature."
His team found that some negative studies didn't get published, and some
study results on effectiveness are inflated.
"Selective publication exaggerated the efficacy of the drugs by 32%
overall," says Turner, an assistant professor of psychiatry and
pharmacology at Oregon Health & Science University in Portland and medical
director of the Portland VA Mood Disorders Program. "But for individual
drugs, the efficacy [reported in published studies] increased from between 11%
to 69%." The study is published this week in The New England Journal of
Study Details: Effectiveness of Antidepressants
Turner decided to do the study after his three-year stint at the FDA,
working as a reviewer on drug studies from 1998 to 2001.
For the study, he and his colleagues zeroed in on 12 antidepressants that
had been approved by the FDA between 1987 and 2004. They looked at 74
FDA-registered studies involving 12,564 patients, comparing the FDA reviews of
the studies with study results published in medical journals.
The published results on the effectiveness of antidepressants didn't always
jibe with the FDA review of the study. For instance:
- The FDA viewed 38 studies as positive, and all but one were published in
- Of the 36 other studies viewed by the FDA as having negative or
questionable results, 22 were not published and 11 were published in a way that
Turner's team believed reported a positive outcome. (That might be
accomplished, Turner says, by looking at statistics differently or using a
different rating system for depression, for instance.)
- While the FDA reviews concluded that 51% of the studies had positive
results for the antidepressants, the published literature reported that 94% of
the studies had positive results.
- Among the drugs looked at were Prozac, Cymbalta, Paxil, and Zoloft.
Effectiveness of Antidepressants: The Rules and the Disconnect
In the U.S., drug companies must register with the FDA all trials they
intend to use to support their request to market a drug, Turner says, and then
report those results. The FDA analyzes their results and goes back over the raw
data to see if they come to the same conclusions.
Exactly why the FDA reviews and the published results don't agree isn't
known, Turner says.
Besides looking at statistics differently, he says, it might be a failure by
the pharmaceutical companies or researcher to submit the manuscript, a decision
by medical journal editors or reviewers not to publish a study result, or a
combination of those factors.